{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T04:42:01Z","timestamp":1774327321957,"version":"3.50.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s00347-024-02021-9","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T11:02:31Z","timestamp":1709031751000},"page":"245-258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Wundheilung der Kornea \u2013 Pharmakologische Therapie","Corneal wound healing\u2014Pharmacological treatment"],"prefix":"10.1007","volume":"121","author":[{"given":"Tobias","family":"Brockmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Brockmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Fuchsluger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Pleyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Walckling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"2021_CR1","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00347-021-01423-3","volume":"118","author":"T Brockmann","year":"2021","unstructured":"Brockmann\u00a0T, Walckling\u00a0M, Brockmann\u00a0C, Fuchsluger\u00a0TMA, Pleyer\u00a0U (2021) Corneal wound healing-Pathophysiology and principles. Ophthalmologe 118:1167\u20131177. https:\/\/doi.org\/10.1007\/s00347-021-01423-3","journal-title":"Ophthalmologe"},{"key":"2021_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.preteyeres.2007.12.002","volume":"27","author":"S Saika","year":"2008","unstructured":"Saika\u00a0S et\u00a0al (2008) Fibrotic disorders in the eye: targets of gene therapy. Prog Retin Eye Res 27:177\u2013196. https:\/\/doi.org\/10.1016\/j.preteyeres.2007.12.002","journal-title":"Prog Retin Eye Res"},{"key":"2021_CR3","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3144\/expresspolymlett.2008.90","volume":"2","author":"S Kamel","year":"2008","unstructured":"Kamel\u00a0S, Ali\u00a0N, Jahangir\u00a0K, Shah\u00a0SM, El-Gendy\u00a0AA (2008) Pharmaceutical significance of cellulose: A\u00a0review. Express Polym Lett 2:758\u2013778","journal-title":"Express Polym Lett"},{"key":"2021_CR4","doi-asserted-by":"publisher","first-page":"783","DOI":"10.2147\/OPTH.S13773","volume":"5","author":"U Benelli","year":"2011","unstructured":"Benelli\u00a0U (2011) Systane lubricant eye drops in the management of ocular dryness. Clin Ophthalmol 5:783\u2013790. https:\/\/doi.org\/10.2147\/OPTH.S13773","journal-title":"Clin Ophthalmol"},{"key":"2021_CR5","unstructured":"Geerling G (2019) et\u00a0al. Leitlinie Nr.\u00a011, Trockenes Auge. 15. https:\/\/www.dog.org\/wp-content\/uploads\/2009\/09\/leit11.pdf"},{"key":"2021_CR6","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","volume":"15","author":"L Jones","year":"2017","unstructured":"Jones\u00a0L et\u00a0al (2017) TFOS DEWS II Management and Therapy Report. Ocul Surf 15:575\u2013628. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.006","journal-title":"Ocul Surf"},{"key":"2021_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40265-021-01660-5","volume":"82","author":"DH Dang","year":"2022","unstructured":"Dang\u00a0DH, Riaz\u00a0KM, Karamichos\u00a0D (2022) Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets. Drugs 82:145\u2013167. https:\/\/doi.org\/10.1007\/s40265-021-01660-5","journal-title":"Drugs"},{"key":"2021_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/OPTO.S350185","volume":"15","author":"DA Semp","year":"2023","unstructured":"Semp\u00a0DA, Beeson\u00a0D, Sheppard\u00a0AL, Dutta\u00a0D, Wolffsohn\u00a0JS (2023) Artificial Tears: A\u00a0Systematic Review. Clin Optom 15:9\u201327. https:\/\/doi.org\/10.2147\/OPTO.S350185","journal-title":"Clin Optom"},{"key":"2021_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jtos.2016.08.004","volume":"15","author":"A Lambiase","year":"2017","unstructured":"Lambiase\u00a0A et\u00a0al (2017) A\u00a0Two-Week, Randomized, Double-masked Study to Evaluate Safety and Efficacy of Lubricin (150\u202f\u03bcg\/mL) Eye Drops Versus Sodium Hyaluronate (HA) 0.18\u202f% Eye Drops (Vismed\u00ae) in Patients with Moderate Dry Eye Disease. Ocul Surf 15:77\u201387. https:\/\/doi.org\/10.1016\/j.jtos.2016.08.004","journal-title":"Ocul Surf"},{"key":"2021_CR10","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1001\/jamaophthalmol.2013.2385","volume":"131","author":"TA Schmidt","year":"2013","unstructured":"Schmidt\u00a0TA et\u00a0al (2013) Transcription, translation, and function of lubricin, a\u00a0boundary lubricant, at the ocular surface. JAMA Ophthalmol 131:766\u2013776. https:\/\/doi.org\/10.1001\/jamaophthalmol.2013.2385","journal-title":"JAMA Ophthalmol"},{"key":"2021_CR11","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.survophthal.2021.07.008","volume":"67","author":"Y Eghtedari","year":"2022","unstructured":"Eghtedari\u00a0Y, Oh\u00a0LJ, Girolamo\u00a0ND, Watson\u00a0SL (2022) The role of topical N\u2011acetylcysteine in ocular therapeutics. Surv Ophthalmol 67:608\u2013622. https:\/\/doi.org\/10.1016\/j.survophthal.2021.07.008","journal-title":"Surv Ophthalmol"},{"key":"2021_CR12","doi-asserted-by":"publisher","first-page":"107916","DOI":"10.1016\/j.pharmthera.2021.107916","volume":"228","author":"B Pedre","year":"2021","unstructured":"Pedre\u00a0B, Barayeu\u00a0U, Ezeri\u0146a\u00a0D, Dick\u00a0TP (2021) The mechanism of action of N\u2011acetylcysteine (NAC): The emerging role of H. Pharmacol Ther 228:107916. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107916","journal-title":"Pharmacol Ther"},{"key":"2021_CR13","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1007\/s10792-023-02751-w","volume":"43","author":"H Sabur","year":"2023","unstructured":"Sabur\u00a0H, Acar\u00a0M (2023) Dexpanthenol\/sodium hyaluronate eye drops for corneal epithelial healing following corneal cross-linking in patients with keratoconus. Int Ophthalmol 43:3461\u20133469. https:\/\/doi.org\/10.1007\/s10792-023-02751-w","journal-title":"Int Ophthalmol"},{"key":"2021_CR14","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1080\/09546634.2017.1325310","volume":"28","author":"E Proksch","year":"2017","unstructured":"Proksch\u00a0E, de Bony\u00a0R, Trapp\u00a0S, Boudon\u00a0S (2017) Topical use of dexpanthenol: a\u00a070th\u00a0anniversary article. J\u00a0Dermatolog Treat 28:766\u2013773. https:\/\/doi.org\/10.1080\/09546634.2017.1325310","journal-title":"J Dermatolog Treat"},{"key":"2021_CR15","doi-asserted-by":"publisher","first-page":"108269","DOI":"10.1016\/j.exer.2020.108269","volume":"201","author":"R Mencucci","year":"2020","unstructured":"Mencucci\u00a0R et\u00a0al (2020) A\u00a0new ophthalmic formulation containing antiseptics and dexpanthenol: In vitro antimicrobial activity and effects on corneal and conjunctival epithelial cells. Exp Eye Res 201:108269. https:\/\/doi.org\/10.1016\/j.exer.2020.108269","journal-title":"Exp Eye Res"},{"key":"2021_CR16","doi-asserted-by":"publisher","first-page":"e540","DOI":"10.1111\/j.1755-3768.2012.02496.x","volume":"90","author":"EC Kim","year":"2012","unstructured":"Kim\u00a0EC, Kim\u00a0TK, Park\u00a0SH, Kim\u00a0MS (2012) The wound healing effects of vitamin\u00a0A eye drops after a\u00a0corneal alkali burn in rats. Acta Ophthalmol 90:e540\u2013e546. https:\/\/doi.org\/10.1111\/j.1755-3768.2012.02496.x","journal-title":"Acta Ophthalmol"},{"key":"2021_CR17","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/2406646","author":"M Li","year":"2021","unstructured":"Li\u00a0M, Chen\u00a0Z, Liu\u00a0L, Ma\u00a0X, Zou\u00a0J (2021) Topical Vitamin\u00a0C Promotes the Recovery of Corneal Alkali Burns in Mice. J\u00a0Ophthalmol. https:\/\/doi.org\/10.1155\/2021\/2406646","journal-title":"J Ophthalmol"},{"key":"2021_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/biom13121754","author":"X Lu","year":"2023","unstructured":"Lu\u00a0X, Chen\u00a0Z, Lu\u00a0J, Watsky\u00a0MA (2023) Effects of 1,25-Vitamin\u00a0D3 and 24,25-Vitamin\u00a0D3 on Corneal Nerve Regeneration in Diabetic Mice. Biomolecules. https:\/\/doi.org\/10.3390\/biom13121754","journal-title":"Biomolecules"},{"key":"2021_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1136\/bjo.85.5.537","volume":"85","author":"M Vetrugno","year":"2001","unstructured":"Vetrugno\u00a0M, Maino\u00a0A, Cardia\u00a0G, Quaranta\u00a0GM, Cardia\u00a0L (2001) A\u00a0randomised, double masked, clinical trial of high dose vitamin\u00a0A and vitamin\u00a0E supplementation after photorefractive keratectomy. Br J Ophthalmol 85:537\u2013539. https:\/\/doi.org\/10.1136\/bjo.85.5.537","journal-title":"Br J Ophthalmol"},{"key":"2021_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000342196","volume":"229","author":"P Fogagnolo","year":"2013","unstructured":"Fogagnolo\u00a0P et\u00a0al (2013) The effects of topical coenzyme Q10 and vitamin\u00a0E D\u2011\u03b1-tocopheryl polyethylene glycol 1000 succinate after cataract surgery: a\u00a0clinical and in vivo confocal study. Ophthalmologica 229:26\u201331. https:\/\/doi.org\/10.1159\/000342196","journal-title":"Ophthalmologica"},{"key":"2021_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/ICO.0000000000000307","volume":"34","author":"JS Weiss","year":"2015","unstructured":"Weiss\u00a0JS et\u00a0al (2015) IC3D classification of corneal dystrophies\u2014edition 2. Cornea 34:117\u2013159. https:\/\/doi.org\/10.1097\/ICO.0000000000000307","journal-title":"Cornea"},{"key":"2021_CR22","doi-asserted-by":"publisher","first-page":"e32796","DOI":"10.7759\/cureus.32796","volume":"14","author":"M Tsatsos","year":"2022","unstructured":"Tsatsos\u00a0M, Matsou\u00a0A, Soultanidis\u00a0M, Athanasiadis\u00a0IK (2022) Safety and Efficacy of Hypertonic Sodium Chloride 5\u202f% Ointment for Recurrent Corneal Erosion Syndrome. Cureus 14:e32796. https:\/\/doi.org\/10.7759\/cureus.32796","journal-title":"Cureus"},{"key":"2021_CR23","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s00347-009-2057-3","volume":"106","author":"JD Unterlauft","year":"2009","unstructured":"Unterlauft\u00a0JD, Kohlhaas\u00a0M, Hofbauer\u00a0I, Kasper\u00a0K, Geerling\u00a0G (2009) Albumin eye drops for treatment of ocular surface diseases. Ophthalmologe 106:932\u2013937. https:\/\/doi.org\/10.1007\/s00347-009-2057-3","journal-title":"Ophthalmologe"},{"key":"2021_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00347-022-01677-5","volume":"120","author":"L Weischnur","year":"2023","unstructured":"Weischnur\u00a0L et\u00a0al (2023) Autologous serum eye drops for therapy-resistant epithelial defects of the cornea : Impact of underlying disease and simultaneous amniotic transplantation in 990 applications. Ophthalmologie 120:43\u201351. https:\/\/doi.org\/10.1007\/s00347-022-01677-5","journal-title":"Ophthalmologie"},{"key":"2021_CR25","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00063-021-00875-4","volume":"116","author":"T Mayerh\u00f6fer","year":"2021","unstructured":"Mayerh\u00f6fer\u00a0T, Wiedermann\u00a0CJ, Joannidis\u00a0M (2021) Use of albumin : State of the art. Med Klin Intensivmed Notfmed 116:655\u2013664. https:\/\/doi.org\/10.1007\/s00063-021-00875-4","journal-title":"Med Klin Intensivmed Notfmed"},{"key":"2021_CR26","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.3747\/co.22.2620","volume":"22","author":"JT Seki","year":"2015","unstructured":"Seki\u00a0JT et\u00a0al (2015) Human albumin eye drops as a\u00a0therapeutic option for the management of keratoconjunctivitis sicca secondary to chronic graft-versus-host disease after stem-cell allografting. Curr Oncol 22:e357\u2013363. https:\/\/doi.org\/10.3747\/co.22.2620","journal-title":"Curr Oncol"},{"key":"2021_CR27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1089\/jop.2014.0161","volume":"31","author":"M Schargus","year":"2015","unstructured":"Schargus\u00a0M, Kohlhaas\u00a0M, Unterlauft\u00a0JD (2015) Treatment of severe ocular surface disorders with albumin eye drops. J\u00a0Ocul Pharmacol Ther 31:291\u2013295. https:\/\/doi.org\/10.1089\/jop.2014.0161","journal-title":"J Ocul Pharmacol Ther"},{"key":"2021_CR28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3238\/arztebl.2011.0243","volume":"108","author":"D Meller","year":"2011","unstructured":"Meller\u00a0D, Pauklin\u00a0M, Thomasen\u00a0H, Westekemper\u00a0H, Steuhl\u00a0KP (2011) Amniotic membrane transplantation in the human eye. Dtsch \u00c4rztebl Int 108:243\u2013248. https:\/\/doi.org\/10.3238\/arztebl.2011.0243","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"2021_CR29","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1055\/s-0034-1383393","volume":"232","author":"T Stachon","year":"2015","unstructured":"Stachon\u00a0T et\u00a0al (2015) Growth Factors and Interleukins in Amniotic Membrane Tissue Homogenate. Klin Monbl Augenheilkd 232:858\u2013862. https:\/\/doi.org\/10.1055\/s-0034-1383393","journal-title":"Klin Monbl Augenheilkd"},{"key":"2021_CR30","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3109\/02713683.2016.1164189","volume":"42","author":"M Bischoff","year":"2017","unstructured":"Bischoff\u00a0M (2017) Growth Factor and Interleukin Concentrations in Amniotic Membrane-Conditioned Medium. Curr Eye Res 42:174\u2013180. https:\/\/doi.org\/10.3109\/02713683.2016.1164189","journal-title":"Curr Eye Res"},{"key":"2021_CR31","doi-asserted-by":"publisher","first-page":"A13","DOI":"10.1136\/bmjophth-2022-EEBA.30","volume":"7","author":"E Agusti","year":"2022","unstructured":"Agusti\u00a0E et\u00a0al (2022) 30\u202fA new step on amniotic membrane extract eye drops (AMEED) development for the treatment of severe ocular surface pathologies. BMJ Open Ophthalmol 7:A13. https:\/\/doi.org\/10.1136\/bmjophth-2022-EEBA.30","journal-title":"BMJ Open Ophthalmol"},{"key":"2021_CR32","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/s13346-020-00843-z","volume":"11","author":"SA Gaballa","year":"2021","unstructured":"Gaballa\u00a0SA et\u00a0al (2021) Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Deliv Transl Res 11:866\u2013893. https:\/\/doi.org\/10.1007\/s13346-020-00843-z","journal-title":"Drug Deliv Transl Res"},{"key":"2021_CR33","doi-asserted-by":"publisher","first-page":"e1118","DOI":"10.1002\/vetr.1118","volume":"190","author":"HE Jost","year":"2022","unstructured":"Jost\u00a0HE, Keenan\u00a0AV, Keys\u00a0DA, Myrna\u00a0KE, Diehl\u00a0KA (2022) Effect of topical non-steroidal anti-inflammatory drugs on healing times and complications in dogs with spontaneous chronic corneal epithelial defects. Vet Rec 190:e1118. https:\/\/doi.org\/10.1002\/vetr.1118","journal-title":"Vet Rec"},{"key":"2021_CR34","doi-asserted-by":"publisher","first-page":"CD015091","DOI":"10.1002\/14651858.CD015091.pub2","volume":"8","author":"M Sulewski","year":"2023","unstructured":"Sulewski\u00a0M et\u00a0al (2023) Topical ophthalmic anesthetics for corneal abrasions. Cochrane Database Syst Rev 8:CD15091. https:\/\/doi.org\/10.1002\/14651858.CD015091.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"2021_CR35","doi-asserted-by":"publisher","first-page":"CD009781","DOI":"10.1002\/14651858.CD009781.pub2","volume":"5","author":"A Wakai","year":"2017","unstructured":"Wakai\u00a0A et\u00a0al (2017) Topical non-steroidal anti-inflammatory drugs for analgesia in traumatic corneal abrasions. Cochrane Database Syst Rev 5:CD9781. https:\/\/doi.org\/10.1002\/14651858.CD009781.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"2021_CR36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3928\/1081-597X-20020301-08","volume":"18","author":"J Narv\u00e1ez","year":"2002","unstructured":"Narv\u00e1ez\u00a0J, Kroll\u00a0P, Guzek\u00a0JP (2002) Effect of topical diclofenac and ketorolac on patient discomfort and corneal sensitivity. J\u00a0Refract Surg 18:145\u2013148. https:\/\/doi.org\/10.3928\/1081-597X-20020301-08","journal-title":"J Refract Surg"},{"issue":"2","key":"2021_CR37","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/eye.2000.55","volume":"14","author":"P Aragona","year":"2000","unstructured":"Aragona\u00a0P, Tripodi\u00a0G, Spinella\u00a0R, Lagan\u00e0\u00a0E, Ferreri\u00a0G (2000) The effects of the topical administration of non-steroidal anti-inflammatory drugs on corneal epithelium and corneal sensitivity in normal subjects. Eye 14(2):206\u2013210. https:\/\/doi.org\/10.1038\/eye.2000.55","journal-title":"Eye"},{"key":"2021_CR38","doi-asserted-by":"publisher","first-page":"678","DOI":"10.5301\/ejo.5001002","volume":"27","author":"C Baudouin","year":"2017","unstructured":"Baudouin\u00a0C et\u00a0al (2017) One-Year Efficacy and Safety of 0.1\u202f% Cyclosporine a\u00a0Cationic Emulsion in the Treatment of Severe Dry Eye Disease. Eur J Ophthalmol 27:678\u2013685. https:\/\/doi.org\/10.5301\/ejo.5001002","journal-title":"Eur J Ophthalmol"},{"key":"2021_CR39","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jcrs.2010.11.035","volume":"37","author":"CJ Nien","year":"2011","unstructured":"Nien\u00a0CJ, Flynn\u00a0KJ, Chang\u00a0M, Brown\u00a0D, Jester\u00a0JV (2011) Reducing peak corneal haze after photorefractive keratectomy in rabbits: prednisolone acetate 1.00\u202f% versus cyclosporine A 0.05. J\u00a0Cataract Refract Surg 37:937\u2013944. https:\/\/doi.org\/10.1016\/j.jcrs.2010.11.035","journal-title":"J Cataract Refract Surg"},{"key":"2021_CR40","doi-asserted-by":"publisher","first-page":"251584141987036","DOI":"10.1177\/2515841419870366","volume":"11","author":"SL Haber","year":"2019","unstructured":"Haber\u00a0SL et\u00a0al (2019) Lifitegrast: a\u00a0novel drug for patients with dry eye disease. Ther Adv Ophthalmol 11:2515841419870366. https:\/\/doi.org\/10.1177\/2515841419870366","journal-title":"Ther Adv Ophthalmol"},{"issue":"Suppl 1","key":"2021_CR41","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1097\/ICL.0000000000000601","volume":"46","author":"AY Tong","year":"2020","unstructured":"Tong\u00a0AY, Passi\u00a0SF, Gupta\u00a0PK (2020) Clinical Outcomes of Lifitegrast 5\u202f% Ophthalmic Solution in the Treatment of Dry Eye Disease. Eye Contact Lens 46(Suppl 1):S20\u2013S24. https:\/\/doi.org\/10.1097\/ICL.0000000000000601","journal-title":"Eye Contact Lens"},{"key":"2021_CR42","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/1346-8138.14501","volume":"45","author":"M Ohtsuki","year":"2018","unstructured":"Ohtsuki\u00a0M, Morimoto\u00a0H, Nakagawa\u00a0H (2018) Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits. J\u00a0Dermatol 45:936\u2013942. https:\/\/doi.org\/10.1111\/1346-8138.14501","journal-title":"J Dermatol"},{"key":"2021_CR43","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1080\/14656566.2017.1372748","volume":"18","author":"ED Donnenfeld","year":"2017","unstructured":"Donnenfeld\u00a0ED, Perry\u00a0HD, Nattis\u00a0AS, Rosenberg\u00a0ED (2017) Lifitegrast for the treatment of dry eye disease in adults. Expert Opin Pharmacother 18:1517\u20131524. https:\/\/doi.org\/10.1080\/14656566.2017.1372748","journal-title":"Expert Opin Pharmacother"},{"key":"2021_CR44","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/ICO.0000000000001408","volume":"37","author":"MN Hashemian","year":"2018","unstructured":"Hashemian\u00a0MN et\u00a0al (2018) Topical Tacrolimus as Adjuvant Therapy to Corticosteroids in Acute Endothelial Graft Rejection After Penetrating Keratoplasty: A\u00a0Randomized Controlled Trial. Cornea 37:307\u2013312. https:\/\/doi.org\/10.1097\/ICO.0000000000001408","journal-title":"Cornea"},{"key":"2021_CR45","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.ophtha.2016.02.044","volume":"123","author":"TB Abud","year":"2016","unstructured":"Abud\u00a0TB et\u00a0al (2016) A\u00a0Clinical Trial Comparing the Safety and Efficacy of Topical Tacrolimus versus Methylprednisolone in Ocular Graft-versus-Host Disease. Ophthalmology 123:1449\u20131457. https:\/\/doi.org\/10.1016\/j.ophtha.2016.02.044","journal-title":"Ophthalmology"},{"key":"2021_CR46","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1097\/ICO.0000000000000918","volume":"35","author":"S Chatterjee","year":"2016","unstructured":"Chatterjee\u00a0S, Agrawal\u00a0D (2016) Tacrolimus in Corticosteroid-Refractory Vernal Keratoconjunctivitis. Cornea 35:1444\u20131448. https:\/\/doi.org\/10.1097\/ICO.0000000000000918","journal-title":"Cornea"},{"key":"2021_CR47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/ICO.0000000000002692","volume":"41","author":"A Hirota","year":"2022","unstructured":"Hirota\u00a0A, Shoji\u00a0J, Inada\u00a0N, Shiraki\u00a0Y, Yamagami\u00a0S (2022) Evaluation of Clinical Efficacy and Safety of Prolonged Treatment of Vernal and Atopic Keratoconjunctivitis Using Topical Tacrolimus. Cornea 41:23\u201330. https:\/\/doi.org\/10.1097\/ICO.0000000000002692","journal-title":"Cornea"},{"key":"2021_CR48","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.2147\/DDDT.S175297","volume":"12","author":"L Chen","year":"2018","unstructured":"Chen\u00a0L et\u00a0al (2018) The long-term effect of tacrolimus on alkali burn-induced corneal neovascularization and inflammation surpasses that of anti-vascular endothelial growth factor. Drug Des Devel Ther 12:2959\u20132969. https:\/\/doi.org\/10.2147\/DDDT.S175297","journal-title":"Drug Des Devel Ther"},{"key":"2021_CR49","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1089\/jop.2018.0054","volume":"34","author":"CH Yoon","year":"2018","unstructured":"Yoon\u00a0CH, Park\u00a0JW, Ryu\u00a0JS, Kim\u00a0MK, Oh\u00a0JY (2018) Corneal Toxicity of Topical Tacrolimus Ointment in Mice with Corneal Epithelial Injury. J\u00a0Ocul Pharmacol Ther 34:685\u2013691. https:\/\/doi.org\/10.1089\/jop.2018.0054","journal-title":"J Ocul Pharmacol Ther"},{"key":"2021_CR50","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/00003226-199207000-00007","volume":"11","author":"JC Pastor","year":"1992","unstructured":"Pastor\u00a0JC, Calonge\u00a0M (1992) Epidermal growth factor and corneal wound healing. A\u00a0multicenter study. Cornea 11:311\u2013314. https:\/\/doi.org\/10.1097\/00003226-199207000-00007","journal-title":"Cornea"},{"key":"2021_CR51","doi-asserted-by":"publisher","first-page":"11350","DOI":"10.1038\/s41598-023-37776-9","volume":"13","author":"SA Pot","year":"2023","unstructured":"Pot\u00a0SA, Lin\u00a0Z, Shiu\u00a0J, Benn\u00a0MC, Vogel\u00a0V (2023) Growth factors and mechano-regulated reciprocal crosstalk with extracellular matrix tune the keratocyte-fibroblast\/myofibroblast transition. Sci Rep 13:11350. https:\/\/doi.org\/10.1038\/s41598-023-37776-9","journal-title":"Sci Rep"},{"key":"2021_CR52","doi-asserted-by":"publisher","first-page":"105127","DOI":"10.1016\/j.jbc.2023.105127","volume":"299","author":"L Li","year":"2023","unstructured":"Li\u00a0L et\u00a0al (2023) rhFGF-21 accelerates corneal epithelial wound healing through the attenuation of oxidative stress and inflammatory mediators in diabetic mice. J\u00a0Biol Chem 299:105127. https:\/\/doi.org\/10.1016\/j.jbc.2023.105127","journal-title":"J Biol Chem"},{"key":"2021_CR53","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ophtha.2019.08.020","volume":"127","author":"SC Pflugfelder","year":"2020","unstructured":"Pflugfelder\u00a0SC et\u00a0al (2020) Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A\u00a0Multicenter Randomized Vehicle-Controlled Pivotal Trial. Ophthalmology 127:14\u201326. https:\/\/doi.org\/10.1016\/j.ophtha.2019.08.020","journal-title":"Ophthalmology"},{"key":"2021_CR54","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40265-020-01289-w","volume":"80","author":"ED Deeks","year":"2020","unstructured":"Deeks\u00a0ED, Lamb\u00a0YN (2020) Cenegermin: A\u00a0Review in Neurotrophic Keratitis. Drugs 80:489\u2013494. https:\/\/doi.org\/10.1007\/s40265-020-01289-w","journal-title":"Drugs"},{"key":"2021_CR55","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.ajpath.2020.08.006","volume":"190","author":"S Yang","year":"2020","unstructured":"Yang\u00a0S et\u00a0al (2020) Insulin Promotes Corneal Nerve Repair and Wound Healing in Type\u00a01 Diabetic Mice by Enhancing Wnt\/\u03b2-Catenin Signaling. Am J Pathol 190:2237\u20132250. https:\/\/doi.org\/10.1016\/j.ajpath.2020.08.006","journal-title":"Am J Pathol"},{"key":"2021_CR56","doi-asserted-by":"publisher","first-page":"930","DOI":"10.4239\/wjd.v14.i6.930","volume":"14","author":"CY Leong","year":"2023","unstructured":"Leong\u00a0CY, Naffi\u00a0AA, Wan Abdul Halim\u00a0WH, Bastion\u00a0MC (2023) Usage of topical insulin for the treatment of diabetic keratopathy, including corneal epithelial defects. World J Diabetes 14:930\u2013938. https:\/\/doi.org\/10.4239\/wjd.v14.i6.930","journal-title":"World J Diabetes"},{"key":"2021_CR57","first-page":"963","volume":"43","author":"EM Rocha","year":"2002","unstructured":"Rocha\u00a0EM et\u00a0al (2002) Identification of insulin in the tear film and insulin receptor and IGF\u20111 receptor on the human ocular surface. Invest Ophthalmol Vis Sci 43:963\u2013967","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2021_CR58","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1097\/ICO.0000000000003308","volume":"42","author":"AM Dasrilsyah","year":"2023","unstructured":"Dasrilsyah\u00a0AM et\u00a0al (2023) Randomized Clinical Trial of Topical Insulin Versus Artificial Tears for Healing Rates of Iatrogenic Corneal Epithelial Defects Induced During Vitreoretinal Surgery in Diabetics. Cornea 42:1395\u20131403. https:\/\/doi.org\/10.1097\/ICO.0000000000003308","journal-title":"Cornea"},{"key":"2021_CR59","doi-asserted-by":"publisher","first-page":"418","DOI":"10.22608\/APO.201780","volume":"6","author":"S Fai","year":"2017","unstructured":"Fai\u00a0S, Ahem\u00a0A, Mustapha\u00a0M, Mohd Noh\u00a0UK, Bastion\u00a0MC (2017) Randomized Controlled Trial of Topical Insulin for Healing Corneal Epithelial Defects Induced During Vitreoretinal Surgery in Diabetics. Asia Pac J Ophthalmol 6:418\u2013424. https:\/\/doi.org\/10.22608\/APO.201780","journal-title":"Asia Pac J Ophthalmol"},{"key":"2021_CR60","first-page":"457","volume":"32","author":"R Lin","year":"1996","unstructured":"Lin\u00a0R, Yang\u00a0D, Guo\u00a0F (1996) An experimental study on immune mechanism after alkali burn in the anterior segment of rabbit eye. Zhonghua Yan Ke Za Zhi 32:457\u2013459","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"2021_CR61","first-page":"1945","volume":"31","author":"BJ Mondino","year":"1990","unstructured":"Mondino\u00a0BJ, Sumner\u00a0HL (1990) Generation of complement-derived anaphylatoxins in normal human donor corneas. Invest Ophthalmol Vis Sci 31:1945\u20131949","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2021_CR62","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2019.8083","author":"T Brockmann","year":"2019","unstructured":"Brockmann\u00a0T (2019) Influence of the complement system on corneal wound healing. Acta Ophthalmol. https:\/\/doi.org\/10.1111\/j.1755-3768.2019.8083","journal-title":"Acta Ophthalmol"},{"key":"2021_CR63","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fimmu.2014.00402","volume":"5","author":"SS Bohlson","year":"2014","unstructured":"Bohlson\u00a0SS, O\u2019Conner\u00a0SD, Hulsebus\u00a0HJ, Ho\u00a0MM, Fraser\u00a0DA (2014) Complement, c1q, and c1q-related molecules regulate macrophage polarization. Front Immunol 5:402. https:\/\/doi.org\/10.3389\/fimmu.2014.00402","journal-title":"Front Immunol"},{"key":"2021_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12103564","author":"K Honda","year":"2023","unstructured":"Honda\u00a0K, Saraya\u00a0T, Ishii\u00a0H (2023) A\u00a0Real-World Prognosis in Idiopathic Pulmonary Fibrosis: A\u00a0Special Reference to the Role of Antifibrotic Agents for the Elderly. J\u00a0Clin Med. https:\/\/doi.org\/10.3390\/jcm12103564","journal-title":"J Clin Med"},{"key":"2021_CR65","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1513\/AnnalsATS.202103-342OC","volume":"19","author":"M Ghazipura","year":"2022","unstructured":"Ghazipura\u00a0M et\u00a0al (2022) Pirfenidone in Progressive Pulmonary Fibrosis: A\u00a0Systematic Review and Meta-Analysis. Ann Am Thorac Soc 19:1030\u20131039. https:\/\/doi.org\/10.1513\/AnnalsATS.202103-342OC","journal-title":"Ann Am Thorac Soc"},{"key":"2021_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020316","author":"CD Diaz-Palomera","year":"2022","unstructured":"Diaz-Palomera\u00a0CD et\u00a0al (2022) Topical Pirfenidone-Loaded Liposomes Ophthalmic Formulation Reduces Haze Development after Corneal Alkali Burn in Mice. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics14020316","journal-title":"Pharmaceutics"},{"key":"2021_CR67","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.intimp.2018.08.032","volume":"64","author":"N Jiang","year":"2018","unstructured":"Jiang\u00a0N et\u00a0al (2018) The role of pirfenidone in alkali burn rat cornea. Int Immunopharmacol 64:78\u201385. https:\/\/doi.org\/10.1016\/j.intimp.2018.08.032","journal-title":"Int Immunopharmacol"},{"key":"2021_CR68","doi-asserted-by":"publisher","first-page":"840","DOI":"10.7150\/ijms.11579","volume":"12","author":"DA la Lopez-de Mora","year":"2015","unstructured":"la Lopez-de Mora\u00a0DA et\u00a0al (2015) Role and New Insights of Pirfenidone in Fibrotic Diseases. Int J Med Sci 12:840\u2013847. https:\/\/doi.org\/10.7150\/ijms.11579","journal-title":"Int J Med Sci"},{"key":"2021_CR69","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/ICU.0000000000000579","volume":"30","author":"D Garcerant","year":"2019","unstructured":"Garcerant\u00a0D et\u00a0al (2019) Descemet\u2019s stripping without endothelial keratoplasty. Curr Opin Ophthalmol 30:275\u2013285. https:\/\/doi.org\/10.1097\/ICU.0000000000000579","journal-title":"Curr Opin Ophthalmol"},{"key":"2021_CR70","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000003449","author":"M Rizk","year":"2023","unstructured":"Rizk\u00a0M et\u00a0al (2023) Long-Term Follow-Up of Descemet Stripping Only: Data Up to 7 Years Postoperatively. Cornea. https:\/\/doi.org\/10.1097\/ICO.0000000000003449","journal-title":"Cornea"},{"key":"2021_CR71","first-page":"101","volume":"7","author":"M Moshirfar","year":"2018","unstructured":"Moshirfar\u00a0M et\u00a0al (2018) Use of Rho kinase Inhibitors in Ophthalmology: A\u00a0Review of the Literature. Med Hypothesis Discov Innov Ophthalmol 7:101\u2013111","journal-title":"Med Hypothesis Discov Innov Ophthalmol"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-024-02021-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-024-02021-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-024-02021-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T15:04:59Z","timestamp":1712243099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-024-02021-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2021"],"URL":"https:\/\/doi.org\/10.1007\/s00347-024-02021-9","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,27]]},"assertion":[{"value":"2 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>T.\u00a0Brockmann<\/b>: A. Finanzielle Interessen: 2022 und 2023 Johnson & Johnson Educational Grant, 2020 DOG-Patent-Preis 2020, 2020 ESCRS Pioneer Award 2020\/2021 | . \u2013 Patentver\u00f6ffentlichung WO2019243555A1. \u2013 B. Nichtfinanzielle Interessen: Angestellter Augenarzt, Klinik und Poliklinik f\u00fcr Augenheilkunde, Universit\u00e4tsmedizin Rostock; Professor, Ernst-Abbe Hochschule Jena | Mitgliedschaften: ESCRS (European Society of Cataract and Refractive Surgeons); DOG (Deutsche Ophthalmologische Gesellschaft), Mitglied der Sektion DOG-Kornea; DGII (Deutschsprachigen Gesellschaft f\u00fcr Intraokularlinsen-Implantation, interventionelle und refraktive Chirurgie); VNDA (Vereinigung Norddeutscher Augen\u00e4rzte). <b>A.\u00a0Simon<\/b>: A.\u00a0Finanzielle Interessen: A.\u00a0Simon gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Dozent (Lehrkraft f\u00fcr besondere Aufgaben) f\u00fcr das Fachgebiet Optometrie an der Ernst-Abbe-Hochschule in Jena; Angestellter Wissenschaftlicher Mitarbeiter f\u00fcr das Fachgebiet Optometrie an der Ernst-Abbe-Hochschule in Jena. <b>C.\u00a0Brockmann<\/b>: A. Finanzielle Interessen: C.\u00a0Brockmann gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B. Nichtfinanzielle Interessen: Angestellte Fach\u00e4rztin f\u00fcr Augenheilkunde, Klinik und Poliklinik f\u00fcr Augenheilkunde, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin; Angestellte Fach\u00e4rztin f\u00fcr Augenheilkunde, Klinik und Poliklinik f\u00fcr Augenheilkunde, Universit\u00e4tsmedizin Rostock | Mitgliedschaft: Deutsche Ophthalmologische Gesellschaft (DOG). <b>T.\u00a0Fuchsluger<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: DGFG, BMBF.\u00a0\u2013 Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: Bausch & Lomb, Santen, Alcon, Bayer, Thea Pharma.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Generalsekret\u00e4r, EVER, Vorstand, VNDA. <b>U.\u00a0Pleyer<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung: Deutsche Forschungsgemeinschaft, BMBF, European Union \u2022 Referentenhonorar\/Reisekostenerstattung als passiver Teilnehmer: Honorare: AbbVie, Alcon, Allergan, Alimera, Bausch und Lomb, Bayer, Novartis, Santen, Thea \u2022 Ich, mein Ehe\u2011\/Partner oder Kind(er) halten Patent\/Gesch\u00e4ftsanteile\/Aktien o.\u202f\u00c4. an einer im Bereich der Medizin aktiven Firma: Bayer, Biontech (Aktien)\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Oberarzt, Klinik f\u00fcr Augenheilkunde, Charit\u00e9 Universit\u00e4tsmedizin Berlin | Mitgliedschaft\/Funktion in Interessenverb\u00e4nden: Sprecher der Sektion: Uveitis\/DOG seit 2014 | Schwerpunkt wissenschaftlicher klinischer T\u00e4tigkeiten: Leiter der Sprechstunde \u201eTerti\u00e4rzentrum f\u00fcr entz\u00fcndliche Augenerkrankungen\u201c 1994 bis heute | Bis 2022 Sekret\u00e4r: Berlin-Brandenburgische Augen\u00e4rzte | Bis 2022 Vorstandsmitglied: Deutsche UVEITIS Arbeitsgemeinschaft DUAG e.\u202fV. U.\u00a0Pleyer ist Mitglied des Herausgeberboards von <i>Die Ophthalmologie<\/i>. Er war nicht an der Begutachtung dieses Manuskripts durch die Zeitschrift oder an Entscheidungen in Bezug auf dieses Manuskript beteiligt. <b>M.\u00a0Walckling<\/b>: A. Finanzielle Interessen: Johnson & Johnson Educational Grant. \u2013 B. Nichtfinanzielle Interessen: Augenklinik der Universit\u00e4tsmedizin Rostock, Position Oberarzt | Mitgliedschaften: DOG, ESCRS.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}